Cardiovascular Disease Risk Algorithms Valid for Black Adults

This article originally appeared here.
Share this content:
Cardiovascular Disease Risk Algorithms Valid for Black Adults
Cardiovascular Disease Risk Algorithms Valid for Black Adults

MONDAY, Feb. 29, 2016 (HealthDay News) -- Current cardiovascular disease (CVD) risk algorithms are valid for black adults, according to a study published online Feb. 24 in JAMA Cardiology.

Ervin R. Fox, M.D., M.P.H., from the University of Mississippi Medical Center in Jackson, and colleagues developed and validated risk prediction models for CVD incidence in black adults in the Jackson Heart Study (JHS). Data were included for 3,689 participants (mean age at baseline, 53 years).

The researchers found that 270 participants experienced a first cardiovascular disease event over a median of 9.1 years. Modest improvement was seen with a simple combination of standard CVD risk factors, B-type natriuretic peptide, and ankle-brachial index, compared with a model without B-type natriuretic peptide and ankle-brachial index (C-statistics, 0.79). The reclassification improvement was not significantly different for this model versus the American College of Cardiology (ACC)/American Heart Association (AHA) CVD Pooled Cohort risk equations or the Framingham Risk Score (FHS). In the Atherosclerosis Risk in Communities and Multi-Ethnic Study of Atherosclerosis data, the models discriminated reasonably well (C-statistic range, 0.70 to 0.77).

"Our findings using the JHS data in the present study are valuable because they confirm that current FHS and ACC/AHA risk algorithms work well in black individuals and are not easily improved on," the authors write. "A unique risk calculator for black adults may not be necessary."

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths